ZEVRA THERAPEUTICS, INC. (ZVRA) Insider Trading -- Recent Executive & Director Transactions

10 insiders reported 41 Form 4 transactions for ZEVRA THERAPEUTICS, INC. (ZVRA) over the past 18 months (most recent 2026-06-23). Recent activity: Thompson Rahsaan (Chief Legal & Compliance) Buy 66,667 shares, Thompson Rahsaan (Chief Legal & Compliance) Sell 34,557 shares, Thompson Rahsaan (Chief Legal & Compliance) Sell 1,794 shares, Bode John B (Director) Buy 39,200 shares, Bode John B (Director) Buy 39,200 shares. Source: SEC Form 4.

DateInsiderTitleTypeSharesValue
2026-06-23Thompson RahsaanChief Legal & ComplianceBuy66,667$0
2026-06-23Thompson RahsaanChief Legal & ComplianceSell34,557$438,304
2026-05-13Thompson RahsaanChief Legal & ComplianceSell1,794$20,272
2026-03-26Bode John BDirectorBuy39,200$194,824
2026-03-26Bode John BDirectorBuy39,200$191,688
2026-02-10McFarlane Neil F.President and CEOBuy37,500$0
2026-02-10McFarlane Neil F.President and CEOSell14,625$125,190
2026-02-04Schafer JoshuaCCOSell10,500$96,495
2026-02-04Sangiovanni Timothy J.SVP, Finance & Corp ControllerSell3,000$27,540
2026-02-02McFarlane Neil F.President and CEOBuy233,334$0
2026-02-02McFarlane Neil F.President and CEOSell91,000$853,580
2026-02-02Sangiovanni Timothy J.SVP, Finance & Corp ControllerBuy6,333$0
2026-02-02Sangiovanni Timothy J.SVP, Finance & Corp ControllerBuy11,666$0
2026-02-02Schafer JoshuaCCOBuy11,333$0
2026-02-02Schafer JoshuaCCOSell3,375$29,801
2026-02-02Schafer JoshuaCCOBuy35,334$0
2026-02-02Thompson RahsaanChief Legal & ComplianceBuy11,333$0
2026-02-02Thompson RahsaanChief Legal & ComplianceSell4,080$36,026
2026-02-02Quartel Adrian WChief Medical OfficerBuy11,333$0
2026-02-02Quartel Adrian WChief Medical OfficerSell4,533$40,026
2026-02-02Sangiovanni Timothy J.SVP, Finance & Corp ControllerSell1,750$15,435
2026-01-07Clifton R. LaDuaneInsiderBuy140,667$0
2026-01-07Clifton R. LaDuaneInsiderSell48,513$434,676
2025-10-10McFarlane Neil F.President and CEOSell19,500$210,990
2025-10-10McFarlane Neil F.President and CEOBuy50,000$0

Source: SEC Form 4 filings · as of 2026-06-23